Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization

Vaccine

Volumn 28, Issue 8, 2010, Pages 1975-1986

  Starodubova, Elizaveta ^a,b,c   Boberg, Andreas ^a,d   Ivanov, Alexander ^c   Latyshev, Oleg ^b   Petrakova, Natalia ^b   Kuzmenko, Yulia ^c   Litvina, Marina ^e   Chernousov, Alexander ^e   Kochetkov, Sergey ^c   Karpov, Vadim ^c   Wahren, Britta ^a,d   Isaguliants, Maria G ^a,b,d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^d KAROLINSKA INSTITUTE   (Sweden)

^e INSTITUTE OF IMMUNOLOGY   (Russian Federation)

Author keywords

break of tolerance; DNA immunization; drug resistance; fusion protein; HIV 1; IFN gamma; LAMP 1; reverse transcritpase; seroreversion; Th1 Th2 type of immune response

Indexed keywords

EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FUSION GENE; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; VIRUS GENE; WILD TYPE;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CROSS REACTIONS; CYTOKINES; DRUG RESISTANCE, VIRAL; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 76949089303     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.098     Document Type: Article

References (50)

1. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
2. Popovic M., Sarngadharan M.G., Read E., and Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224 (1984) 497-500
3. Pomerantz R.J., and Horn D.L. Twenty years of therapy for HIV-1 infection. Nat Med 9 (2003) 867-873
4. Jacobson M.A., and French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 12, Suppl. A (1998) S157-S163
5. Dornadula G., Nunnari G., Vanella M., Roman J., Babinchak T., DeSimone J., et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 183 (2001) 1682-1687
6. Craigo J.K., Patterson B.K., Paranjpe S., Kulka K., Ding M., Mellors J., et al. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res Hum Retroviruses 20 (2004) 1196-1209
7. Arts E.J., and Wainberg M.A. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 40 (1996) 527-540
8. Richman D.D. Drug resistance in relation to pathogenesis. AIDS 9, Suppl. A (1995) S49-S53
9. Wainberg M.A., Gu Z., Gao Q., Arts E., Geleziunas R., Bour S., et al. Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr 6, Suppl. 1 (1993) S36-S46
10. Aleman S., Soderbarg K., Visco-Comandini U., Sitbon G., and Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16 (2002) 1039-1044
11. Tozzi V., Corpolongo A., Bellagamba R., and Narciso P. Managing patients with sexual transmission of drug-resistant HIV. Sex Health 2 (2005) 135-142
12. Turner D., and Wainberg M.A. HIV transmission and primary drug resistance. AIDS Rev 8 (2006) 17-23
13. Haas G., Samri A., Gomard E., Hosmalin A., Duntze J., Bouley J.M., et al. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS 12 (1998) 1427-1436
14. Harrer E., Harrer T., Barbosa P., Feinberg M., Johnson R.P., Buchbinder S., et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 173 (1996) 476-479
15. Laurence J., Saunders A., and Kulkosky J. Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity. Science 235 (1987) 1501-1504
16. Neumuller M., Karlsson A., Lennerstrand J., Kallander C.F., Sandstrom E., Holmberg V., et al. HIV-1 reverse transcriptase inhibiting antibody titer in serum: relation to disease progression and to core-antibody levels. J Med Virol 36 (1992) 283-291
17. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 16 (2008) 138-145
18. Casazza J.P., Betts M.R., Hill B.J., Brenchley J.M., Price D.A., Douek D.C., et al. Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy. J Virol 79 (2005) 3653-3663
19. Boberg A., and Isaguliants M. Vaccination against drug resistance in HIV infection. Expert Rev Vaccines 7 (2008) 131-145
20. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
21. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198 (2008) 1482-1490
22. Shephard E., Burgers W.A., Van Harmelen J.H., Monroe J.E., Greenhalgh T., Williamson C., et al. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24 (2008) 207-217
23. Starodubova E., Boberg A., Kashuba E.V., Wahren B., Karpov V., and Isaguliants M. HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. Vaccine 24 (2006) 4541-4547
24. Isaguliants M.G., Zuber B., Boberg A., Sjostrand D., Belikov S.V., Rollman E., et al. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model. Vaccine 22 (2004) 1810-1819
25. Starodubova E.S., Boberg A., Litvina M., Morozov A., Petrakova N.V., Timofeev A., et al. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response. Vaccine 26 (2008) 5170-5176
26. Anwar A., Chandrasekaran A., Ng M.L., Marques E., and August J.T. West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology 332 (2005) 66-77
27. Lu Y., Raviprakash K., Leao I.C., Chikhlikar P.R., Ewing D., Anwar A., et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 21 (2003) 2178-2189
28. Gupta V., Tabiin T.M., Sun K., Chandrasekaran A., Anwar A., Yang K., et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology 347 (2006) 127-139
29. Arruda L.B., Sim D., Chikhlikar P.R., Maciel Jr. M., Akasaki K., August J.T., et al. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J Immunol 177 (2006) 2265-2275
30. Chikhlikar P., Barros de Arruda L., Agrawal S., Byrne B., Guggino W., August J.T., et al. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 323 (2004) 220-232
31. Marques Jr. E.T., Chikhlikar P., de Arruda L.B., Leao I.C., Lu Y., Wong J., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 278 (2003) 37926-37936
32. Chen J.W., Murphy T.L., Willingham M.C., Pastan I., and August J.T. Identification of two lysosomal membrane glycoproteins. J Cell Biol 101 (1985) 85-95
33. Karpenko L.I., Ilyichev A.A., Eroshkin A.M., Lebedev L.R., Uzhachenko R.V., Nekrasova N.A., et al. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies. Vaccine 25 (2007) 4312-4323
34. Mason R.D., Bowmer M.I., Howley C.M., Gallant M., Myers J.C., and Grant M.D. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 172 (2004) 7212-7219
35. Samri A., Haas G., Duntze J., Bouley J.M., Calvez V., Katlama C., et al. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 74 (2000) 9306-9312
36. Schmitt M., Harrer E., Goldwich A., Bauerle M., Graedner I., Kalden J.R., et al. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14 (2000) 653-658
37. Karlsson A.C., Chapman J.M., Heiken B.D., Hoh R., Kallas E.G., Martin J.N., et al. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol 81 (2007) 11543-11548
38. Mueller S.M., Schaetz B., Eismann K., Bergmann S., Bauerle M., Schmitt-Haendle M., et al. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease. J Virol 81 (2007) 2887-2898
39. Metzner K.J., Binley J.M., Gettie A., Marx P., Nixon D.F., and Connor R.I. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology 3 (2006) 97
40. Isaguliants M.G., Belikov S.V., Starodubova E.S., Gizatullin R.Z., Rollman E., Zuber B., et al. Mutations conferring drug resistance affect eukaryotic expression of HIV type 1 reverse transcriptase. AIDS Res Hum Retroviruses 20 (2004) 191-201
41. Altstein A.D., Gitelman A.K., Smirnov Y.A., Piskareva L.M., Zakharova L.G., Pashvykina G.V., et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 151 (2006) 921-931
42. Chikhlikar P., de Arruda L.B., Maciel M., Silvera P., Lewis M.G., August J.T., et al. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS ONE 1 (2006) e135
43. Beekman N.J., van Veelen P.A., van Hall T., Neisig A., Sijts A., Camps M., et al. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol 164 (2000) 1898-1905
44. Draenert R., Le Gall S., Pfafferott K.J., Leslie A.J., Chetty P., Brander C., et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 199 (2004) 905-915
45. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., et al. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 78 (2004) 1324-1332
46. Zimbwa P., Milicic A., Frater J., Scriba T.J., Willis A., Goulder P.J., et al. Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. J Virol 81 (2007) 2031-2038
47. Lewe G., and Flugel R.M. Comparative analysis of the retroviral pol and env protein sequences reveal different evolutionary trees. Virus Genes 3 (1990) 195-204
48. Isaguliants M.G., Pokrovskaya K., Kashuba V.I., Pokholok D., Hinkula J., Wahren B., et al. Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. FEBS Lett 447 (1999) 232-236
49. Ivanov A.V., Korovina A.N., Tunitskaya V.L., Kostyuk D.A., Rechinsky V.O., Kukhanova M.K., et al. Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expr Purif 48 (2006) 14-23
50. Rechinskii V.O., Barbashov S.F., Degtiarev I.L., Vorob'ev S.M., Liakhov D.L., Kostiuk D.A., et al. Reverse transcriptase of the human immunodeficiency virus: cloning, expression in Escherichia coli, purification of the enzyme, and production of monoclonal antibodies. Mol Biol (Mosk) 25 (1991) 1248-1257